FACULTY
Evan L. Siegel, MD, FACP, FACR
Assistant Clinical Professor of Medicine
Georgetown University School of Medicine
Medical Director, Arthritis and Rehabilitation Services
Arthritis and Rheumatism Associates
Rockville, MD
Atul Deodhar, MD, MRCP, DNB, FACR, FACP
Medical Director, Rheumatology Clinics
Professor of Medicine
Division of Arthritis and Rheumatic Diseases
Oregon Health & Science University
Portland, OR
PROGRAM OVERVIEW
This enduring program will present actionable evidence regarding targeted therapies for spondyloarthritis (SpA) and provide strategies for facilitating shared decision making to enable optimal outcomes for patients with these debilitating conditions. Rheumatology clinicians will gain the knowledge and competence to differentiate between SpA conditions and make a timely diagnosis; apply the latest clinical evidence on targeted therapies such as IL-17 antagonists to treatment decisions; and optimize shared decision making and collaboration across the multidisciplinary care team.
TARGET AUDIENCE
This activity is designed to meet the educational needs of rheumatologists, rheumatology NPs, and rheumatology PAs to improve knowledge and competence of these healthcare providers regarding the latest evidence in targeted therapies for SpA conditions, strategies for improving patient-specific, shared decision-making care to advance the optimal outcomes of patients with these debilitating conditions.
LEARNING OBJECTIVES
- Describe the clinical manifestations of SpA conditions to promptly differentiate and diagnose
- Apply the latest clinical evidence for IL-17 antagonists for the management of SpA conditions
- Develop strategies to optimize the shared decision-making efforts and collaboration across the multidisciplinary care team in the management of SpA conditions
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
NURSES (ANCC) CREDIT DESIGNATION
Amedco LLC designates this activity for a maximum of 1.25 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
Dr. Siegel discloses the following:
- Consulting fees from Abbvie, Janssen, Novartis, UCB and BMS
- Speakers’ bureau for Abbvie, Janssen, Horizon and UCB
- Ownership interest in Abbvie, Amgen and Lilly
Dr. Deodhar discloses the following relationships:
- Consulting/Advisory Boards: AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, UCB
- Research Grants: Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, MoonLake, Novartis, Pfizer, UCB
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
- Chris Drury, Medical Director of Med Learning Group, has nothing to disclose.
- Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
- Jessica Feygin, Associate Program Manager of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (Physical, Dietary, etc.). Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: December 07, 2023
EXPIRATION DATE: December 07, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
